A retrospective study showed that overall survival is worse with invasive lobular carcinoma, among other key differences in outcomes and clinicopathologic features.
Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer, after invasive ductal carcinoma (IDC), accounting for 5%–15% of all breast cancers. Several key clinical characteristics have long been appreciated to distinguish ILC from IDC, such as less-clear mammographic visualization and unusual metastatic sites, including serosal surfaces in the abdomen and pelvis.
To better differentiate the clinicopathologic features and outcomes between ILC and IDC, investigators conducted a retrospective cohort study of 3617 ILC patients and 30,045 IDC patients diagnosed between 1990 and 2017 at three large U.S. cancer centers.
Key findings were as follows:
Reviewing Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)